Pharmacy and Pharmaceutical Sciences Commons^™

Rocuronium And Malignant Hyperthermia, Jennifer Quinn Mccann, Ashton E. Beggs

Scholarship and Professional Work – COPHS

Authors response to a comment on: Beggs A, McCann J, Powers J. “Delayed-onset malignant hyperthermia in association with rocuronium use ” Am J Health-Syst Pharm 2012; 69:1128-34.

Delayed-Onset Malignant Hyperthermia In Association With Rocuronium Use, Ashton E. Beggs, Jennifer Quinn Mccann, Jan M. Powers

Scholarship and Professional Work – COPHS

Purpose Two cases of malignant hyperthermia suspected to be related to the use of a nondepolarizing neuromuscular blocker are reported.

Summary A pharmacogenetic disorder that may occur in as many as 1 in 3000 anesthesia procedures, malignant hyperthermia has been linked to the use of certain anesthetic gases and depolarizing neuromuscular blocking agents (e.g., succinylcholine). Although nondepolarizing neuromuscular blockers were cited as contributing to the development of malignant hyperthermia in a small number of published reports, the agents are generally considered safe for use in at-risk patients. Here investigators report two cases in which the nondepolarizing agent rocuronium is thought …